Author:
Gazelakis Kathryn,Majeed Ammar,Kemp William,Di Muzio Bruno,Gerstenmaier Jan,Cheung Wa,Roberts Stuart K.
Abstract
AbstractWhile dysplastic liver nodules in cirrhosis are pre-malignant, little is known about the predictors of hepatocarcinogenesis of these lesions. This was a retrospective observational study of subjects with cirrhosis who had at least one hypervascular, non-malignant intrahepatic nodule on imaging while undergoing outpatient management by a tertiary hepatology referral centre between Jan 2009 and Jan 2019. Clinical and biochemical parameters were collected. The primary endpoint was transformation to hepatocellular carcinoma (HCC) as determined by Liver Imaging Reporting and Data System. During the study period, 163 non-malignant hypervascular nodules were identified in 77 patients; 147 had at least 6 months of follow up imaging and 16 received upfront radiofrequency ablation upon detection. During a median follow up of 38.5 months (IQR 16.5–74.5), 25 (17%) of the 147 hypervascular nodules being monitored transformed to HCC. On multivariate analysis, Child–Pugh grade was found to be the only independent predictor of nodule transformation into HCC (p = 0.02). Those with Child–Pugh B and C liver disease had a 10.1 (95% CI 1.22–83.8; p = 0.03) and 32.6-fold (95% CI 2.3–467; p = 0.01) increased risk respectively for HCC transformation compared to Child–Pugh A subjects. This large, single centre study demonstrates that around 20% of dysplastic nodules in cirrhotic patients undergo hepatocarcinogenesis during follow up, and that Child Pugh grade is the only independent predictor of transformation to HCC. Additional prospective studies are warranted to better understand the risk profile of these nodules, and how best they should be managed.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144(8), 1941–1953 (2019).
2. Bray, F. et al. Erratum: Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin 70, 313 (2020).
3. Observatory TGC. Liver: International Agency for Research on Cancer; 2020, (accessed 9 February 2021); https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf.
4. N’Kontchou, G. et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin. Gastroenterol. Hepatol. 4(8), 1062–1068 (2006).
5. McGlynn, K. A. & London, W. T. Epidemiology and natural history of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 19(1), 3–23 (2005).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献